Anemia drug by Takeda and Affymax is submitted for FDA OK

05/31/2011 | Forbes · Pharmaceutical Business Review Online

Affymax and Takeda Pharmaceutical are seeking FDA approval of peginesatide, a drug candidate for anemia in kidney dialysis patients. The once-monthly drug, formerly called Hematide, appears as safe and effective as epoetin alfa or epoetin beta in stabilizing hemoglobin level, according to results of two Phase III trials.

View Full Article in:

Forbes · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations